Barclays’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,400
| Closed | -$491K | – | 5154 |
|
|
2025
Q4 | $491K | Hold |
1,400
| – | – | ﹤0.01% | 3856 |
|
|
2025
Q3 | $452K | Buy |
1,400
+100
| +8% | +$31.1K | ﹤0.01% | 3871 |
|
|
2025
Q2 | $506K | Sell |
1,300
-11,100
| -90% | -$4.46M | ﹤0.01% | 3757 |
|
|
2025
Q1 | $5.39M | Buy |
12,400
+7,700
| +164% | +$3.09M | ﹤0.01% | 1849 |
|
|
2024
Q4 | $1.73M | Hold |
4,700
| – | – | ﹤0.01% | 2993 |
|
|
2024
Q3 | $2.44M | Sell |
4,700
-14,700
| -76% | -$7.85M | ﹤0.01% | 2692 |
|
|
2024
Q2 | $10.5M | Buy |
19,400
+14,700
| +313% | +$7.77M | ﹤0.01% | 1168 |
|
|
2024
Q1 | $2.44M | Hold |
4,700
| – | – | ﹤0.01% | 2405 |
|
|
2023
Q4 | $2.22M | Sell |
4,700
-4,700
| -50% | -$2.17M | ﹤0.01% | 2831 |
|
|
2023
Q3 | $4.09M | Buy |
+9,400
| New | +$4.26M | ﹤0.01% | 1447 |
|
|
2022
Q1 | – | Sell |
-400
| Closed | -$185K | – | 5118 |
|
|
2021
Q4 | $185K | Buy |
+400
| New | +$168K | ﹤0.01% | 3594 |
|
|
2021
Q1 | – | Sell |
-8,600
| Closed | -$2.76M | – | 4819 |
|
|
2020
Q4 | $2.76M | Buy |
+8,600
| New | +$2.64M | ﹤0.01% | 1989 |
|
|
2020
Q2 | – | Sell |
-31,900
| Closed | -$7.24M | – | 5721 |
|
|
2020
Q1 | $7.24M | Buy |
31,900
+13,900
| +77% | +$3.79M | 0.01% | 1206 |
|
|
2019
Q4 | $5.44M | Sell |
18,000
-13,200
| -42% | -$3.63M | ﹤0.01% | 1919 |
|
|
2019
Q3 | $7.49M | Sell |
31,200
-18,300
| -37% | -$5.01M | ﹤0.01% | 1528 |
|
|
2019
Q2 | $14M | Buy |
49,500
+500
| +1% | +$137K | 0.01% | 1142 |
|
|
2019
Q1 | $14.1M | Buy |
49,000
+16,000
| +48% | +$4.63M | 0.01% | 1028 |
|
|
2018
Q4 | $8.67M | Sell |
33,000
-17,600
| -35% | -$4.84M | 0.01% | 1234 |
|
|
2018
Q3 | $13.9M | Sell |
50,600
-40,500
| -44% | -$10.5M | 0.01% | 1063 |
|
|
2018
Q2 | $21.7M | Buy |
91,100
+15,000
| +20% | +$3.47M | 0.02% | 749 |
|
|
2018
Q1 | $16.7M | Buy |
76,100
+46,300
| +155% | +$10.9M | 0.01% | 933 |
|
|
2017
Q4 | $6.71M | Sell |
29,800
-9,200
| -24% | -$1.96M | 0.01% | 1445 |
|
|
2017
Q3 | $7.41M | Sell |
39,000
-500
| -1% | -$95.2K | 0.01% | 1241 |
|
|
2017
Q2 | $7.43M | Sell |
39,500
-37,900
| -49% | -$6.81M | 0.01% | 1176 |
|
|
2017
Q1 | $12.8M | Sell |
77,400
-21,100
| -21% | -$3.36M | 0.01% | 745 |
|
|
2016
Q4 | $14.2M | Buy |
98,500
+76,200
| +342% | +$10.2M | 0.02% | 774 |
|
|
2016
Q3 | $2.79M | Buy |
22,300
+8,800
| +65% | +$1.14M | ﹤0.01% | 1724 |
|
|
2016
Q2 | $1.77M | Buy |
13,500
+7,100
| +111% | +$971K | ﹤0.01% | 2116 |
|
|
2016
Q1 | $883K | Sell |
6,400
-55,600
| -90% | -$7.43M | ﹤0.01% | 2628 |
|
|
2015
Q4 | $8.62M | Buy |
62,000
+20,000
| +48% | +$2.76M | 0.01% | 974 |
|
|
2015
Q3 | $5.88M | Buy |
42,000
+10,200
| +32% | +$1.53M | 0.01% | 1257 |
|
|
2015
Q2 | $5.21M | Buy |
31,800
+8,000
| +34% | +$1.28M | 0.01% | 1457 |
|
|
2015
Q1 | $3.67M | Sell |
23,800
-11,500
| -33% | -$1.64M | ﹤0.01% | 1797 |
|
|
2014
Q4 | $4.41M | Sell |
35,300
-173,500
| -83% | -$21.4M | ﹤0.01% | 1814 |
|
|
2014
Q3 | $24.8M | Sell |
208,800
-16,600
| -7% | -$1.9M | 0.02% | 616 |
|
|
2014
Q2 | $24.1M | Buy |
225,400
+145,300
| +181% | +$15M | 0.03% | 610 |
|
|
2014
Q1 | $7.93M | Sell |
80,100
-18,800
| -19% | -$1.7M | 0.01% | 1329 |
|
|
2013
Q4 | $9.1M | Sell |
98,900
-39,300
| -28% | -$3.49M | 0.01% | 1320 |
|
|
2013
Q3 | $11.5M | Buy |
138,200
+1,500
| +1% | +$129K | 0.01% | 1044 |
|
|
2013
Q2 | $11.2M | Buy |
+136,700
| New | +$10.2M | 0.01% | 1005 |
|
Other funds holding ELV
VCM
VPM
Barclays's ELV Position: Q1 2026 in Review
Barclays increased its Elevance Health (ELV) stake by 121% in Q1 2026, buying an estimated $151M and bringing the position to 838,900 shares worth $246M. The position accounts for 0.06% of the portfolio, ranked #243.
Barclays first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $582M in Q4 2023. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Barclays held 838,900 shares of Elevance Health worth $246M as of Q1 2026.
- Barclays bought 460,014 Elevance Health shares in Q1 2026, an estimated $151M.
- Elevance Health made up 0.06% of Barclays's portfolio in Q1 2026, its #243 holding.
- Barclays first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
- Barclays's Elevance Health position peaked at $582M in Q4 2023.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.